A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.

Cancer cells frequently harbor defects in DNA repair pathways, leading to genomic instability. This can foster tumorigenesis but also provides a weakness in the tumor that can be exploited therapeutically. Tumors with compromised ability to repair double-strand DNA breaks by homologous recombination, including those with defects in BRCA1 and BRCA2, are highly sensitive to blockade of the repair of DNA single-strand breaks via the inhibition of the enzyme poly(ADP) ribose polymerase. This provides the basis for a novel synthetic lethal approach to cancer therapy.

[1]  Jorge S. Reis-Filho,et al.  Resistance to therapy caused by intragenic deletion in BRCA2 , 2008, Nature.

[2]  A. Venkitaraman,et al.  Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein. , 2003, Genes & development.

[3]  F. Couch,et al.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.

[4]  G. de Murcia,et al.  The PARP superfamily , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[5]  J. Reis-Filho,et al.  Basal-like breast cancer and the BRCA1 phenotype , 2006, Oncogene.

[6]  B. Koller,et al.  Brca1 controls homology-directed DNA repair. , 1999, Molecular cell.

[7]  J. Hoeijmakers,et al.  Chromosomal stability and the DNA double-stranded break connection , 2001, Nature Reviews Genetics.

[8]  R. Kanaar,et al.  Brca2 (XRCC11) Deficiency Results in Radioresistant DNA Synthesis and a Higher Frequency of Spontaneous Deletions , 2002, Molecular and Cellular Biology.

[9]  Kai Rothkamm,et al.  Pathways of DNA Double-Strand Break Repair during the Mammalian Cell Cycle , 2003, Molecular and Cellular Biology.

[10]  A. Tutt,et al.  First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers , 2007 .

[11]  C. Deng,et al.  A targeted disruption of the murine Brca1 gene causes γ-irradiation hypersensitivity and genetic instability , 1998, Oncogene.

[12]  X. Wang,et al.  Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. , 1999, Molecular cell.

[13]  G E Tomlinson,et al.  BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. , 1999, Cancer research.

[14]  R. L. Baldwin,et al.  Improved survival in women with BRCA‐associated ovarian carcinoma , 2003, Cancer.

[15]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[16]  T. Dobzhansky,et al.  Genetics of Natural Populations. Xiii. Recombination and Variability in Populations of Drosophila Pseudoobscura. , 1946, Genetics.

[17]  William D. Foulkes,et al.  Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .

[18]  Luca Pellegrini,et al.  Interaction with the BRCA2 C terminus protects RAD51–DNA filaments from disassembly by BRC repeats , 2007, Nature Structural &Molecular Biology.

[19]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[20]  V. Favaudon,et al.  Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery , 2003, BMC Cell Biology.

[21]  A. Ashworth,et al.  RAD51, BRCA2 and DNA repair: a partial resolution , 2007, Nature Structural &Molecular Biology.

[22]  S. West,et al.  Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. , 2000, Genes & development.

[23]  R. Tuma.  Combining carefully selected drug, patient genetics may lead to total tumor death. , 2007, Journal of the National Cancer Institute.

[24]  E. Plummer.  Inhibition of poly(ADP-ribose) polymerase in cancer. , 2006, Current opinion in pharmacology.

[25]  R. Wooster,et al.  Breast and ovarian cancer. , 2003, The New England journal of medicine.

[26]  A. Ashworth,et al.  BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: An issue of potency , 2005, Cancer biology & therapy.

[27]  C. Mathew,et al.  Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors , 2003, Nature Medicine.

[28]  F. Gage,et al.  Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Tainer,et al.  Structure and function of the double-strand break repair machinery. , 2004, DNA repair.

[30]  M. Jasin,et al.  BRCA2 is required for homology-directed repair of chromosomal breaks. , 2001, Molecular cell.

[31]  J. Hoeijmakers.  Genome maintenance mechanisms for preventing cancer , 2001, Nature.

[32]  J. Boultwood.  Ataxia telangiectasia gene mutations in leukaemia and lymphoma , 2001, Journal of clinical pathology.

[33]  L. Hartwell,et al.  Integrating genetic approaches into the discovery of anticancer drugs. , 1997, Science.

[34]  M. Jasin,et al.  Chromosomal translocation mechanisms at intronic alu elements in mammalian cells. , 2005, Molecular cell.

[35]  A. Ashworth,et al.  Utilizing RNA interference to enhance cancer drug discovery , 2007, Nature Reviews Drug Discovery.

[36]  Manel Esteller,et al.  Mutator pathways unleashed by epigenetic silencing in human cancer. , 2007, Mutagenesis.

[37]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[38]  P. Chambon,et al.  Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. , 1963, Biochemical and biophysical research communications.

[39]  Edward H Egelman,et al.  Stabilization of RAD51 nucleoprotein filaments by the C-terminal region of BRCA2 , 2007, Nature Structural &Molecular Biology.

[40]  Rafael A Irizarry,et al.  Global synthetic-lethality analysis and yeast functional profiling. , 2006, Trends in genetics : TIG.

[41]  Katharina Dittmar,et al.  In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs) , 2005, BMC Genomics.

[42]  E. Wagner,et al.  PARP is important for genomic stability but dispensable in apoptosis. , 1997, Genes & development.

[43]  Jeremy M. Stark,et al.  Genetic Steps of Mammalian Homologous Repair with Distinct Mutagenic Consequences , 2004, Molecular and Cellular Biology.

[44]  A. Ashworth,et al.  The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability , 2006, Oncogene.

[45]  Anne M. Bowcock,et al.  Identification of a RING protein that can interact in vivo with the BRCA1 gene product , 1996, Nature Genetics.

[46]  J. Low,et al.  Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology , 2007, Clinical Cancer Research.

[47]  A. Ashworth,et al.  Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. , 2005, Cold Spring Harbor symposia on quantitative biology.

[48]  S. Kern,et al.  Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition , 2005, Cancer biology & therapy.

[49]  Y. Yamaguchi-Iwai,et al.  Homologous recombination and non‐homologous end‐joining pathways of DNA double‐strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells , 1998, The EMBO journal.

[50]  J. Haber.  DNA recombination: the replication connection. , 1999, Trends in biochemical sciences.

[51]  W. Kaelin.  The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.

[52]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[53]  Alan Ashworth,et al.  Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. , 2006, Cancer research.

[54]  L. Symington.  Focus on recombinational DNA repair , 2005, EMBO reports.

[55]  A. Ashworth,et al.  Mutation in Brca2 stimulates error‐prone homology‐directed repair of DNA double‐strand breaks occurring between repeated sequences , 2001, The EMBO journal.

[56]  Krystyna J. Dillon,et al.  Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase. , 2005, Bioorganic & medicinal chemistry letters.

[57]  B. Ponder,et al.  Involvement of Brca2 in DNA repair. , 1998, Molecular cell.

[58]  T. Helleday,et al.  DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. , 2001, Journal of molecular biology.

[59]  Wen-Hwa Lee,et al.  BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. , 2002, Science.

[60]  R. Sutphen,et al.  Improved survival in BRCA2 carriers with ovarian cancer , 2006, Familial Cancer.

[61]  S. Boulton,et al.  Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. , 1999, Carcinogenesis.

[62]  C. Moskaluk,et al.  Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. , 1996, Cancer research.

[63]  Yonghong Xiao,et al.  Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells , 1997, Cell.

[64]  Luke Hughes-Davies,et al.  EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer , 2003, Cell.